» Articles » PMID: 31114701

Risk of Cardiovascular Event and Mortality in Relation to Refill and Guideline Adherence to Lipid-lowering Medications Among Patients with Type 2 Diabetes Mellitus in Sweden

Overview
Specialty Endocrinology
Date 2019 May 23
PMID 31114701
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To analyze the risk of cardiovascular (CV) events and mortality in relation to adherence to lipid-lowering medications by healthcare centers and patients with type 2 diabetes mellitus (T2DM).

Research Design And Methods: We included 121 914 patients (12% secondary prevention) with T2DM reported by 1363 healthcare centers. Patients initiated lipid-lowering medications between July 2006 and December 2012 and were followed from cessation of the first filled supply until multidose dispensed medications, migration, CV events, death or December 2016. The study period was divided into 4-month intervals through 2014, followed by annual intervals through 2016. Adherence measures were assessed for each interval. Patients' (refill) adherence was measured using the medication possession ratio (MPR). Healthcare centers' (guideline) adherence represented the prescription prevalence of lipid-lowering medications according to guidelines. The risk of CV events and mortality was analyzed for each interval using Cox proportional hazard regression and Kaplan-Meier.

Results: Compared with high-adherent patients (MPR >80%), low-adherent primary prevention patients (MPR ≤80%) showed higher risk of all outcomes: 44%-51 % for CV events, doubled for all-cause mortality and 79%-90% for CV mortality. Corresponding risks for low-adherent secondary prevention patients were 17%-19% for CV events, 88%-97% for all-cause and 66%-79% for CV mortality. Primary prevention patients treated by low-adherent healthcare centers (guideline adherence <48%) had a higher risk of CV events and CV mortality. Otherwise, no difference in the risk of CV events or mortality was observed by guideline adherence level.

Conclusions: Our results demonstrate the importance of high refill adherence and thus the value of individualized care among patients with T2DM.

Citing Articles

Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care.

Morieri M, Longato E, Di Camillo B, Sparacino G, Avogaro A, Fadini G Cardiovasc Diabetol. 2022; 21(1):274.

PMID: 36494815 PMC: 9738028. DOI: 10.1186/s12933-022-01712-4.


Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.

Svensson M, Vilela F, Leosdottir M, Banefelt J, Lindh M, Dun A Ups J Med Sci. 2022; 127.

PMID: 35722183 PMC: 9171571. DOI: 10.48101/ujms.v127.8296.


Monitoring adherence to pharmacological therapy and follow-up examinations among patients with type 2 diabetes in community pharmacies. Results from an experience in Italy.

Spadea T, Onorati R, Baratta F, Pignata I, Parente M, Pannacci L PLoS One. 2021; 16(9):e0256478.

PMID: 34492060 PMC: 8423241. DOI: 10.1371/journal.pone.0256478.


Per-Treatment Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD.

Mallett A, Perrone R, Rangan G, Hawley C, El-Damanawi R, Hiemstra T Kidney Int Rep. 2021; 6(4):1032-1040.

PMID: 33912753 PMC: 8071614. DOI: 10.1016/j.ekir.2021.01.014.


Guideline Adherence and Associated Outcomes in the Treatment of Type 2 Diabetes Mellitus Patients With an Incident Cardiovascular Comorbidity: An Analysis Based on a Large German Claims Dataset.

Gabler M, Picker N, Geier S, Ley L, Aberle J, Lehrke M Diabetes Ther. 2021; 12(4):1209-1226.

PMID: 33710520 PMC: 7994459. DOI: 10.1007/s13300-021-01024-y.


References
1.
. 9. Cardiovascular Disease and Risk Management. Diabetes Care. 2016; 40(Suppl 1):S75-S87. DOI: 10.2337/dc17-S012. View

2.
Berthold H, Gouni-Berthold I, Bohm M, Krone W, Bestehorn K . Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009; 8:25. PMC: 2689197. DOI: 10.1186/1475-2840-8-25. View

3.
Korhonen M, Ruokoniemi P, Ilomaki J, Meretoja A, Helin-Salmivaara A, Huupponen R . Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidemiol Drug Saf. 2015; 25(2):161-9. DOI: 10.1002/pds.3936. View

4.
Eriksson M, Zethelius B, Eeg-Olofsson K, Nilsson P, Gudbjornsdottir S, Cederholm J . Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. Eur J Cardiovasc Prev Rehabil. 2011; 18(1):97-105. DOI: 10.1097/HJR.0b013e32833ba61e. View

5.
Havranek E, Mujahid M, Barr D, Blair I, Cohen M, Cruz-Flores S . Social Determinants of Risk and Outcomes for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2015; 132(9):873-98. DOI: 10.1161/CIR.0000000000000228. View